semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Histologically confirmed advanced or metastatic breast cancer postmenopausal females with amenorrhoea > 12 months and an intact uterus FSH levels within postmenopausal range or have undergone a bilateral oophorectomy ER &/or PR positive previous adjuvant hormone therapy > 12 months prior to enrolment previous adjuvant chemotherapy > 6 months prior to enrolment measurable disease according to and/or non measurable bone disease life expectancy of at least 12 weeks World Health Organisation (WHO) performance status (PS) of 0 to 1  Male life-threatening metastatic visceral disease evidence of clinically active interstitial lung disease ER and PR negative treatment with LHRH analogues < 3 months prior to enrolment patients who have restarted menses or do not have FSH levels within the postmenopausal range treatment with strontium (or other radio pharmaceutical) within the previous 3 months Treatment with hormonotherapy and/or chemotherapy for advanced disease extensive radiotherapy to measurable lesions within the last 4 weeks (i.e. >30% of bone marrow, e.g. whole of pelvis or half of spine)
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Signed informed consent, premenopausal women 18 years or older, histologically or cytologically confirmed locally advanced or metastatic breast cancer, suitable for endocrine treatment, no curative treatment available,, one or more measurable lesions, life expectancy more than 6 months, normal biological parameters  Presence of life-threatening metastases, previous endocrine therapy or chemotherapy for advanced or metastatic disease, any previous treatment with hormone (LH-RH) severe or uncontrolled systemic disease, pituitary adenoma, High risk of medullar compression
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Locally Advanced Breast Cancer Postmenopausal women 2. Primary locally invasive breast cancer 3. Histological confirmed by core needle biopsy, whose tumors are estrogen (ER) and / or progesterone (PgR) positive, defined by core biopsy immunohistochemistry with > 10% positive malignant epithelial cells. 4. Post menopausal status 5. Tumor measurable by clinical examination, mammography and ultrasound  Prior treatment with letrozole or tamoxifen. 2. Patients with bilateral breast tumors 3. Patients who are eligible for breast conserving surgery 4. Evidence of inflammatory breast cancer or distant metastasis. 5. Other concurrent malignant disease 6. Concomitant anti-cancer treatments such as chemotherapy Other protocol-defined
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  DCIS Patients must have suspicion of DCIS or early invasive breast cancer on mammography Patients must have histologically confirmed diagnosis of DCIS or early invasive breast cancer on core biopsy for final registration Patients must be over 18 years of age "Patients must be postmenopausal as defined by one of the following 1. Prior bilateral oophorectomy OR 2. > 12 months since LMP with no prior hysterectomy OR 3. a & b not applicable AND age >=50 Patients must be positive for either ER or PR or both Patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines  Patients must not have diagnosis of osteoporosis (T-score -2.5 according to the WHO)
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Neoplasms Postmenopausal women with metastatic breast cancer, or loco-regional disease recurrence not amenable to treatment by surgery or radiotherapy Postmenopausal status will be defined by any of the following no spontaneous menses for at least 5 years spontaneous menses within the past 5 years but amenorrheic for at least 12 months and estradiol and/or FSH values in the postmenopausal range (while off aromatase inhibitor therapy; levels can have been taken while on tamoxifen but in this case estradiol should be the parameter assessed) bilateral oophorectomy radiation castration and amenorrheic for at least 3 months the use of an LHRH agonist throughout the duration of the trial (for example goserelin 3.6 mg s.c. monthly) Age ≥ 18 years old Patients whose tumors are either estrogen-receptor (ER) and/or progesterone-receptor (PgR) positive (10% or more infiltrating cancer cells exhibiting nuclear staining). Patients will be regarded as ER or PgR positive as long as at least one of the tissues assessed was positive. A positive biochemical test is also acceptable Patients must have a WHO Performance Status Grade 0-2  Patients with tumors which are both estrogen and progesterone receptor negative, or estrogen receptor negative and progesterone receptor unknown or estrogen receptor unknown and progesterone receptor negative Patients with a history of adrenalectomy or hypophysectomy Patients who developed progressive disease while being treated with an aromatase inhibitor Patients with any of the following Absolute Neutrophil Count < 1.5 x 109/L Hemoglobin < 9 g/dl Platelet count < 100 x 109/L AST and ALT > 3 times the upper limit of normal or > 5 times the upper limit of normal if liver metastasis are present Bilirubin > 1.5 upper limit of normal Creatinine > 1.5 x upper limit of normal
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Breast Cancer Diagnosis of breast cancer T2-T4c, any N, M0 disease Clinically staged, as documented by the treating physician, as 1 of the following T4a-c disease for which modified radical mastectomy with negative margins is the goal T2 or T3 disease for which conversion from needing mastectomy to breast conservation is the goal T2 disease for which lumpectomy at first attempt is the goal Primary tumor must be palpable and measure > 2 cm by tape, ruler, or caliper measurements in at least one dimension Must agree to undergo mastectomy or lumpectomy after neoadjuvant aromatase inhibitor therapy No inflammatory breast cancer, defined as clinically significant erythema of the breast and/or documented dermal lymphatic invasion (not direct skin invasion by tumor or peau d'orange without erythema) No distant metastasis (M1)
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Migraine Headache Migraine Headache  Pregnancy and lactation Pre-medication within six hours of being enrolled in the study More than six prior headaches per month Allergy to the study drugs Non-migraine headache Substance abuse Alcohol abuse Diabetes mellitus, or a coexisting condition that might expose the patients to a disproportionately increased risk of a significant adverse event: ischaemic heart disease, peripheral vascular disease, cerebrovascular disease, uncontrolled hypertension (blood pressure >160/95), epilepsy, use of cimetidine, dopamine agonist, cyclopsorin, or oral hypoglycemic agents, hepatic or renal failure, and thyroid disorder
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Histologically confirmed infiltrating carcinoma of the breast meeting any of the following T1-3, any N disease Proven ductal carcinoma in situ Unresected disease Planned mastectomy as definitive surgical procedure Known or suspected metastatic disease allowed provided mastectomy is planned Nonpalpable tumor allowed (e.g., initial T2-3 tumor that responded to preoperative therapy) No inflammatory breast cancer or other T4 features Successful baseline ductogram Baseline nipple aspiration procedure must identify a duct productive of nipple aspirate fluid
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Breast Cancer Diagnosis of ductal carcinoma in situ (DCIS) on core biopsy No evidence of contralateral breast disease or palpable masses on breast examination No presence or suspicion of invasive cancer, including contralateral invasive cancer, on core biopsy and MRI No documented ipsilateral axillary adenopathy Planning to undergo lumpectomy or mastectomy Estrogen receptor (ER)-positive tumor by immunohistochemistry Female patient Premenopausal or postmenopausal Postmenopausal is defined by any of the following No spontaneous menses for >= 1 year
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Breast Neoplasms Fibrocystic Disease of Breast Mammaplasty first visit to a Breast Disease Ambulance for consultation no pregnancy  no severe heart disease (EF > 40%) no therapy with digitalis no acute/chronic inflammatory disease (e.g. RA, M. Crohn) no dysfunction of the Hypothalamo-Pituitary-Adrenal system no severe mental disorder
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 20.0-74.0,  Lymphoma, Low-Grade Patients with CD 20 positive, relapsed/refractory indolent lymphoma. (Regimens of prior chemotherapy are limited to 2; prior rituximab treatments up to 16 times are allowed.) Patients with measurable lesions (> 1.5 cm) Patients who have not received any treatment for more than 4 weeks after completing previous therapies (6 months in the case of antibody therapies) ECOG performance status: 0 Patients with adequately maintained organ functions  Patients with infectious disease, serious complications, serious gastrointestinal symptoms, serious bleeding tendency, serious CNS symptoms, fever </=38 °C, interstitial pneumonia or pulmonary fibrosis, active other malignancies, autoimmune hemolytic anemia or the history of the disease, or glaucoma Patients who are positive for HBs antigen, HCV antibody, or HIV antibody Patients who received G-CSF or transfusion within 1 week before the registration Patients with the history of allergies to purine nucleoside analogue Patients who experienced serious hypersensitivity or anaphylaxis to rituximab or mouse protein-derived products Patients who had ever received prior therapy with fludarabine phosphate injection, pentostatin, cladribine, SH T 586, blood stem cell transplant, or monoclonal antibody therapy other than rituximab to NHL (including radioimmunotherapy) Patients who had progressive disease within 6 months of receiving therapy including rituximab Women who are pregnant, of childbearing potential, or lactating Patients who do not agree to practice contraception
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Infiltrative Breast Cancer patients with infiltrative breast cancer (diagnosed pre-operatively by core biopsy) approval and informed consent  chemotherapy locoregional radiotherapy prevalent axillary lymph node
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Early Breast Cancer Post menopausal woman with a breast cancer and scheduled for an adjuvant treatment with anastrozole WHO performance status 0, 1 or 2 Provision of written informed consent  Recurrence of breast cancer, inflammatory rheumatism treatment by chondromodulator, oral glucocorticoid, aromatase inhibitor, anti estrogen, Herceptin Diabetes treated by insulin Severe renal or hepatic disease Known hypersensitivity to anastrozole
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer postmenopausal women on or off hormone replacement therapy at high risk of developing breast cancer determined by family or personal history postmenopausal women not on hormone replacement therapy for at minimum six months prior to corresponding aspiration willing to participate in companion protocol (KUMC HSC#4601) for random periareolar fine needle aspiration (RPFNA) for correlational studies  women who have been on raloxifene, tamoxifen, letrozole, anastrozole or exemestane within the six months prior to RPFNA
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer History of histologically confirmed breast cancer, meeting 1 of the following staging Ductal carcinoma in situ Stage I-III invasive breast cancer At least 3 months since completion of all intended local and systemic therapy, including mastectomy or lumpectomy with or without radiotherapy, adjuvant chemotherapy, and/or endocrine therapy May have declined recommended treatment provided all treatment intended/agreed upon by the patient and treating physician was completed ≥ 3 months ago At least 1 healthy intact breast No prior radiotherapy or mastectomy Prior biopsies allowed Any hormone-receptor status Female